Senior Project Manager

BRC Therapeutics appoints biopharma veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy. Aug 24, 2026, 11:00 ET Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ - BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, today announced the appointment of Chandra Ramanathan, Ph.D., M.B.A., as Executive Vice President of Commercialization and Strategy. Ramanathan brings more than 30 years of biopharmaceutical leadership spanning drug development, global product launches, commercialization, and external innovation to BRC as the company advances its pipeline and prepares for its next phase of growth. Ramanathan joins BRC from Danaher Corporation, where he served as Vice President and Global Head of Innovation Hubs and Head of External Innovation, Life Sciences Innovation Group (LSIG) building a funnel of product-oriented partnerships across genomic medicine, diagnostics, LSIG, and biomanufacturing. Prior to Danaher, he spent more than 12 years at Bayer, most recently as Global Head of Pharma R&D Open Innovation, where he chaired the Open Innovation Committee overseeing an annual investment budget of more than $90 million across more than 50 academic and biotech partnerships. While leading Bayer's East Coast Innovation Center in Cambridge, MA, Ramanathan built major partnerships with the Broad Institute, MassGeneral Brigham, and Johns Hopkins University. Earlier in his career, Ramanathan led global launch teams behind two approved therapies (Bosulif(R), Aliqopa(R) and contributed to the launches of Orencia(R), and Sprycel(R) across roles at Wyeth (now Pfizer), Bristol Myers Squibb, and Bayer. As the Head of oncology strategic marketing, he grew Bayer's oncology clinical portfolio from two assets to fifteen over five years. His experience spans the full spectrum of drug development and commercialization: external innovation, product development, companion diagnostics strategy, portfolio and launch planning, and building cross-functional global teams across the U.S., Europe, and Asia. "Chandra has spent his career doing precisely what BRC needs next: progressing promising science into the next phase of clinical development and ultimately into approved medicines that reach patients, based on proven growth strategies and commercial infrastructure to get there," said George Hodgin, Founder and CEO of BRC Therapeutics. "He has led launches at some of the most respected companies in our industry, built innovation engines from the ground up, and has a rare ability to move fluidly between science, innovation strategy, and commercial strategy. As we advance our pipeline in CRPS, AIIA, RLS and additional indications and prepare for our next phase of growth, Chandra's judgment, expertise and experience will be invaluable." "BRC is pursuing something genuinely novel: FDA-regulated cannabinoid medicines for patients with too few good options. The company's foundation is innovative science, a strong intellectual property estate, unique and evolving regulatory approach, and an unwavering drive to make a difference for patients," said Chandra Ramanathan. "I've spent my entire career helping companies bridge early science and commercial reality, and I see that same opportunity here. I'm excited to work alongside George and the BRC team as the company moves toward pivotal trials, new opportunities, and ultimately helping patients." Ramanathan currently serves as Chairperson of the Board of Directors of Nucleate, a nonprofit developing the next generation of biotech entrepreneurs, and holds board and advisory roles with the McLean Hospital, the Johns Hopkins University Innovation, Development & Entrepreneurial Advisory Board and Harvard Business School Blavatnik Fellowship Council. He was also a board member with MassBIO and Chair of the Innovation Committee where he recently finished his 9-year term. He is also an Adjunct Assistant Professor at Tufts University School of Medicine. Ramanathan holds an M.B.A. from Columbia Business School and a Ph.D. in Genomics and Bioinformatics from the University of Georgia. BRC Therapeutics (BRC) is a pharmaceutical company focused on developing innovative therapeutics to deliver relief from pain and other symptoms in chronic conditions. BRC's medicines are multimodal and contain cannabinoids at defined ratios. BRC has developed a pipeline of investigational prescription medicines addressing neurological and inflammatory conditions. Investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS), Restless Legs Syndrome (RLS), and Aromatase Inhibitor-Induced Arthralgia (AIIA) and an additional confidential indication. BRC is registered with the Drug Enforcement Administration and is based in Monterey, CA. Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, including without limitation statements about the development, use, benefits and effects of BRC Therapeutics' (BRC) therapeutic product candidates and related technology, future plans for BRC's business and growth, and expected plans with respect to clinical trials, including the number of patients enrolled and timing of patient enrollment. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "design," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. The forward-looking statements made herein speak only as of the date of this press release and, unless otherwise required by law, BRC does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. SOURCE BRC Therapeutics

Danaher Corporation reported Q2 2026 revenue of $6.3 billion, up 5.5% year-over-year, with adjusted diluted EPS rising 8% to $1.94. The company raised its full-year adjusted EPS guidance to $8.45–$8.60, driven by Life Sciences strength and mid-teens bioprocessing order growth. However, Danaher's bioprocessing unit missed expectations, signalling continued softness in biopharma demand. The news sent shares of Sartorius AG lower, which in turn affected Bio-Rad Laboratories, which holds a $5 billion stake in Sartorius. Bio-Rad shares fell about 1% in early trading. Bio-Rad reported Q2 net sales of $651 million, flat year-over-year. Its Life Science segment declined 4.1% to $252 million due to academic funding constraints. On 31 July, Bio-Rad announced a restructuring plan involving headcount reductions and facility closures, expecting $80 million to $90 million in pre-tax charges.

Thermo Fisher Scientific and Danaher, two major life sciences tools companies, both reported better-than-expected second-quarter results, but their recoveries show different trajectories. Thermo Fisher posted 10% revenue growth to $11.99 billion and 13% adjusted EPS growth to $6.03. The company raised guidance citing broad-based demand improvement across pharmaceutical and biotechnology markets. Its Life Sciences Solutions segment grew 13% year-over-year, whilst Analytical Instruments returned to growth after nearly two years of weak demand. Danaher's recovery remains more uneven, though it achieved high-single-digit adjusted EPS growth with improving core growth versus the previous quarter. Thermo Fisher's recovery appears more broad-based across multiple segments, suggesting greater durability. The company continues investing in product innovation, including new Orbitrap mass spectrometers.